BioMarin Pharmaceutical Inc. (BMRN) 当前追踪市盈率 (P/E) 为 30.9, 前瞻市盈率为 12.8. 追踪盈利收益率为 3.24%, 前瞻盈利收益率 7.79%. PEG 0.09 (Peter Lynch 低估标准 ≤1.0). 格雷厄姆数为 $36.04.
本页证实的标准:
SharesGrow 综合评分： 82/100 其中 6/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -21.8 | -0.09 | 4.97 | 12.31 | - |
| 2017 | -132.9 | 1.61 | 5.54 | 11.84 | - |
| 2018 | -195.3 | 5.69 | 5.08 | 10.11 | - |
| 2019 | -634.8 | 9.01 | 4.85 | 8.88 | - |
| 2020 | 18.6 | 0.00 | 3.86 | 8.52 | - |
| 2021 | -252.1 | 2.35 | 3.79 | 8.75 | - |
| 2022 | 135.4 | -0.43 | 4.17 | 9.15 | - |
| 2023 | 108.0 | 6.32 | 3.66 | 7.49 | - |
| 2024 | 29.3 | 0.19 | 2.21 | 4.38 | - |
| 2025 | 32.7 | -1.71 | 1.87 | 3.54 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-3.79 | $1.12B | $-630.21M | -56.4% |
| 2017 | $-0.67 | $1.31B | $-117.04M | -8.9% |
| 2018 | $-0.44 | $1.49B | $-77.21M | -5.2% |
| 2019 | $-0.13 | $1.7B | $-23.85M | -1.4% |
| 2020 | $4.53 | $1.86B | $854.03M | 45.9% |
| 2021 | $-0.35 | $1.85B | $-64.08M | -3.5% |
| 2022 | $0.75 | $2.1B | $141.56M | 6.8% |
| 2023 | $0.87 | $2.42B | $167.65M | 6.9% |
| 2024 | $2.06 | $2.85B | $426.86M | 15% |
| 2025 | $1.80 | $3.22B | $348.9M | 10.8% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $4.32 | $4.09 – $4.89 | $3.62B | $3.6B – $3.66B | 9 |
| 2027 | $5.37 | $4.32 – $5.88 | $4.03B | $3.75B – $4.13B | 8 |
| 2028 | $6.76 | $4.90 – $9.01 | $4.42B | $4.18B – $4.66B | 8 |
| 2029 | $7.57 | $7.19 – $7.96 | $4.79B | $4.61B – $4.98B | 6 |
| 2030 | $8.40 | $7.98 – $8.82 | $5.08B | $4.89B – $5.28B | 6 |
